PS
ELDN icon

Planning Strategies’s Eledon Pharmaceuticals ELDN Stock Holding History

Planning Strategies’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$713 Buy
+181
New +$658 ﹤0.01% 800

Other funds holding ELDN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CCM
Catalio Capital Management New York $532M AUM 166.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Planning Strategies's ELDN Position: Q2 2026 in Review

Planning Strategies opened a new position in Eledon Pharmaceuticals (ELDN) in Q2 2026: 181 shares worth $713. The stake represents ﹤0.01% of the portfolio and ranks #800 among its holdings.

147 funds tracked by Wall St. Rank hold ELDN as of Q2 2026.

  • Planning Strategies held 181 shares of Eledon Pharmaceuticals worth $713 as of Q2 2026.
  • Eledon Pharmaceuticals was a new Planning Strategies position in Q2 2026.
  • Eledon Pharmaceuticals made up ﹤0.01% of Planning Strategies's portfolio in Q2 2026, its #800 holding.
  • 147 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q2 2026.

Based on Planning Strategies's 13F filing for Q2 2026, filed 27 Jul 2026.